Hyperion DeFi (NASDAQ:HYPD) Now Covered by Analysts at Cantor Fitzgerald

Investment analysts at Cantor Fitzgerald initiated coverage on shares of Hyperion DeFi (NASDAQ:HYPD) in a report released on Tuesday, Marketbeat reports. The firm set an “overweight” rating on the stock.

Several other equities research analysts also recently weighed in on the company. Wall Street Zen raised Hyperion DeFi from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $3.00.

Hyperion DeFi Stock Performance

Shares of HYPD traded up $0.06 during mid-day trading on Tuesday, hitting $3.00. 278,911 shares of the company’s stock were exchanged, compared to its average volume of 1,561,553. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 0.11. Hyperion DeFi has a fifty-two week low of $0.85 and a fifty-two week high of $17.99. The business’s 50 day moving average is $5.51 and its two-hundred day moving average is $7.53. The firm has a market capitalization of $24.51 million, a P/E ratio of -0.74 and a beta of 2.80.

Hyperion DeFi (NASDAQ:HYPD) last posted its quarterly earnings data on Friday, November 14th. The company reported $0.05 EPS for the quarter. Hyperion DeFi had a negative return on equity of 119.59% and a negative net margin of 62,238.41%.The firm had revenue of $0.36 million during the quarter. On average, equities analysts expect that Hyperion DeFi will post -41.6 earnings per share for the current year.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.